Cargando…
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were designed to allow specific targeting of highly potent cytotoxic agents to tumor cells whilst sparing normal cells. Frequent toxic...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966843/ https://www.ncbi.nlm.nih.gov/pubmed/27045800 http://dx.doi.org/10.1080/19420862.2016.1156829 |